The road to individualized treatment for CLL
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
When BOPA met HOPA: collaborations in oncology pharmacy
Susannah Koontz Webb
Biosimilars: informing patients and physicians
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?